In vitro and in vivo activity of two second generation platinum analogs in murine bladder cancer.
The activity of cis-diamminedichloroplatinum(II) was compared to two second generation platinum analogs, cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) and cis-dichlorotransdihydroxybisisopropylamine platinum(IV) in the N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide-induced murine bladder tumor model and a tumor colony assay. Murine drug testing revealed that all three drugs were active against the MBT-2 tumor line, although cis-diamminedichloroplatinum(II) was more active than its analogs. All drugs produced enhanced inhibition of clonal growth with increasing drug exposure times. Cis-diamminedichloroplatinum(II) was more active against MBT-2 cells in the plateau growth phase versus the log growth phase after a one hour drug exposure. Similar differential activity depending upon the proliferative state of MBT-2 was not seen with the two platinum analogs. These two platinum analogs have somewhat less activity in vivo and in vitro than cis-diamminedichloroplatinum(II) and would be predicted to be less effective clinically in human bladder cancer than the parent compound.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D016190:Carboplatin; D002460:Cell Line; D002945:Cisplatin / Q000494:pharmacology* / Q000627:therapeutic use; D003114:Colony-Forming Units Assay; D005200:FANFT / Q000633:toxicity; D005260:Female; D051379:Mice; D009944:Organoplatinum Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D014410:Tumor Stem Cell Assay; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced / Q000188:drug therapy*
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C023359:iproplatin; D005200:FANFT; D016190:Carboplatin; D002945:Cisplatin